Q2 Earnings Estimate for Progyny Issued By Leerink Partnrs

Progyny, Inc. (NASDAQ:PGNY - Free Report) - Research analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for shares of Progyny in a research note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.18 for the quarter, up from their prior estimate of $0.15. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Progyny's current full-year earnings is $0.60 per share. Leerink Partnrs also issued estimates for Progyny's Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.64 EPS.

A number of other brokerages have also commented on PGNY. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research note on Monday, March 31st. Canaccord Genuity Group dropped their price objective on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Finally, Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a report on Tuesday, July 8th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $24.09.

Progyny Stock Performance

Shares of PGNY stock traded up $0.26 during trading hours on Friday, reaching $23.47. The company had a trading volume of 724,706 shares, compared to its average volume of 1,719,186. The business has a fifty day moving average price of $21.81 and a 200-day moving average price of $21.63. Progyny has a one year low of $13.39 and a one year high of $30.42. The firm has a market cap of $2.01 billion, a PE ratio of 41.18, a price-to-earnings-growth ratio of 2.39 and a beta of 1.31.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same quarter in the prior year, the firm earned $0.17 earnings per share. The business's revenue was up 16.5% compared to the same quarter last year.

Institutional Investors Weigh In On Progyny

Large investors have recently bought and sold shares of the business. Signaturefd LLC lifted its stake in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after acquiring an additional 1,355 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Progyny during the first quarter valued at about $44,000. Militia Capital Partners LP increased its holdings in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after acquiring an additional 1,000 shares in the last quarter. Natixis acquired a new position in shares of Progyny during the fourth quarter valued at about $69,000. Finally, Brooklyn Investment Group increased its holdings in shares of Progyny by 5,216.4% during the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after acquiring an additional 3,182 shares in the last quarter. Institutional investors own 94.93% of the company's stock.

Insiders Place Their Bets

In related news, Director Cheryl Scott sold 2,675 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the sale, the director owned 14,112 shares in the company, valued at approximately $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.40% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.